HRRM TESTING IN METASTATIC PROSTATE CANCER

Objecte

Topic: Prostate cancer.

Destination: Pfizer will fund training initiatives aimed at enhancing the understanding of the need for conducting HRM (homologous recombination repair gene mutation) testing for metastatic prostate cancer in clinical practice.

Budget: 500.000$.

Duration: Less than 1 year.

Are you interested in this call?

Estàs interessat?

Omple el següent formulari per rebre més informació: